Abstracts tagged "Biologic response modifiers and pediatric rheumatology"

Abstract Number: 390 • 2016 ACR/ARHP Annual Meeting
Use, Safety and Efficacy of Zrc 3197, a Biosimilar Candidate for Reference Adalimumab (Humira) from a Tertiary Pediatric Rheumatology Centre in India
Manjari Agarwal¹, Abhay Shivpuri², Sumidha Mittal³, Amit Khosla⁴ and Sujata Sawhney⁵, ¹Institute of Child Health, Attending Consultant, New Delhi, India, ²Division of Pediatric Rheumatology,Institute of Child Health, Post Doctoral Fellow, New Delhi, India, ³Post Doctoral Fellow, New Delhi, India, ⁴Department of Ophthalmology,Sir Ganga Ram Hospital, Senior Consultant, New Delhi, India, ⁵Paediatric rheumatology, Senior Consultant, New Delhi, India
Background/Purpose: Reference Adalimumab is not available in our country but biosimilar ZRC 3197 is(1). This is lower priced and as healthcare is primarily self funded…